(Q38246143)

31 August 2017

Ganitumab for the treatment of small-cell lung cancer (English)

1 reference

31 August 2017

Enriqueta Felip

3

0 references

author name string

Pablo Martínez

series ordinal

1

1 reference

PubMed ID

25189625

31 August 2017

Paula Alexandra Sales Fidalgo

series ordinal

2

1 reference

PubMed ID

25189625

31 August 2017

language of work or name

English

0 references

publication date

5 September 2014

1 reference

Expert Opinion on Investigational Drugs

31 August 2017

1 reference

31 August 2017

23

1 reference

31 August 2017

10

1 reference

31 August 2017

1423-1432

1 reference

31 August 2017

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung ca

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Small cell lung cancer and targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

The effects of insulin-like growth factors on tumorigenesis and neoplastic growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

The type 1 insulin-like growth factor receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Insulin-like growth factors and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Type I insulin-like growth factor receptor as a therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Targeting insulin-like growth factor pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Structure and functional analysis of the IGF-II/IGF2R interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

IGF2: epigenetic regulation and role in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor I-induced activation of extracellular signal-regulated kinase in oral carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.951434

10.1517/13543784.2014.951434

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

25189625